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Abstract: It can be assumed that higher SARS-CoV-2 infection risk is associated with higher COVID-
19 vaccination intentions, although evidence is scarce. In this large and representative survey of
6007 adults aged 18–64 years and residing in France, 8.1% (95% CI, 7.5–8.8) reported a prior SARS-
CoV-2 infection in December 2020, with regional variations according to an East–West gradient
(p < 0.0001). In participants without prior SARS-CoV-2 infection, COVID-19 vaccine hesitancy was
substantial, including 41.3% (95% CI, 39.8–42.8) outright refusal of COVID-19 vaccination. Taking
into account five characteristics of the first approved vaccines (efficacy, duration of immunity, safety,
country of the vaccine manufacturer, and place of administration) as well as the initial setting of
the mass vaccination campaign in France, COVID-19 vaccine acceptance would reach 43.6% (95%
CI, 43.0–44.1) at best among working-age adults without prior SARS-CoV-2 infection. COVID-19
vaccine acceptance was primarily driven by vaccine characteristics, sociodemographic and attitudinal
factors. Considering the region of residency as a proxy of the likelihood of getting infected, our study
findings do not support the assumption that SARS-CoV-2 infection risk is associated with COVID-19
vaccine acceptance.
Keywords: SARS-CoV-2; COVID-19; mass vaccination; anti-vaccination behavior; vaccine hesitancy;
survey experiment; discrete choice experiment; France
1. Introduction
On 11 March 2020, the World Health Organization declared the severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2) outbreak in China to be a pandemic [1]. All
European countries implemented “stop and go” strategies with more or less restrictive
non-pharmaceutical interventions during 2020 to reduce SARS-CoV-2 transmission [2,3]
and coronavirus disease-19 (COVID-19) mortality [4,5]. By mid-November 2020, COVID-19
vaccination had become a reality with the announcement of safe and effective candidate
vaccines meeting all primary endpoints in large phase 3 trials [6–8]. Mass vaccination
campaigns started in the European Union (EU) immediately after the approval of a first
COVID-19 vaccine on 21 December 2020 [9]. However, beyond global constraints on vac-
cine supply for mass vaccination campaigns, COVID-19 vaccine hesitancy may represent
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a major hurdle to reaching herd immunity and controlling the SARS-CoV-2 pandemic
without non-pharmaceutical interventions in each country [10–12].
Vaccine hesitancy is defined by a delay in acceptance or refusal of vaccination despite
availability of vaccination services [13]. Vaccine hesitancy is multifactorial [14] and varies
across countries and over time [15]. In this regard, COVID-19 vaccine hesitancy is no
exception [16–18]. However, high-income countries were diversely affected by the SARS-
CoV-2 pandemic [4,5]. It may be assumed that countries with higher prevalence rates of
SARS-CoV-2 infection may experience higher COVID-19 vaccination intentions [19–21] and
reach herd immunity at a faster rate due to the combined effect of higher natural immunity
and vaccine uptake.
The large and rapid initial peak of SARS-CoV-2 infection in the North–East and Ile-
de-France regions of France [22] provides a unique natural experiment to understand the
association between SARS-CoV-2 infection risk and COVID-19 vaccination intentions at
the regional level. The main aim of this study was to assess this association in the French
working-age population (18–64 years) who is at high risk of SARS-CoV-2 infection as com-
pared to the elderly [22,23]. We conducted a survey experiment in December 2020 among
a large and representative sample of twelve regions of France and found that COVID-19
vaccine hesitancy was substantial and primarily driven by vaccine characteristics, sociode-
mographic and attitudinal factors, but unrelated to SARS-CoV-2 infection risk.
2. Materials and Methods
2.1. Study Design
We conducted a cross-sectional survey among a representative sample of 6007 adults
aged 18–64 years residing in twelve of thirteen regions of France (Auvergne-Rhône-
Alpes (ARA), Bourgogne-Franche-Comté (BFC), Bretagne (BRE), Centre-Val de Loire
(CVL), Grand Est (GES), Hauts-de-France (HDF), Ile-de-France (IDF), Normandie (NOR),
Nouvelle-Aquitaine (NAQ), Occitanie (OCC), Pays-de-la-Loire (PDL), and Provence-Alpes-
Côte-d’Azur (PAC)). The survey was fielded from 30 November to 16 December 2020,
during the second wave of the SARS-CoV-2 pandemic and the regional extension of the
curfew to the whole country [2]. Participants were selected for this survey from an online
survey research panel, which was developed and is maintained by BVA (Paris, France) and
consists of more than 700,000 French adults. Pre-existing information on the participants
was used by BVA to determine eligibility and draw a stratified random sample, with
oversampling of participants with low response rates. Sampling was stratified to match
French official census statistics by region of residency (gender, age group, education level,
household size, and area of residence). The survey was not conducted in Corsica, as this
thirteenth region was underrepresented in the BVA online survey research panel.
Participants completed a self-reported online questionnaire eliciting background in-
formation, past vaccination behavior, risk factors of a severe form of COVID-19, COVID-19
experience, and risk perceptions about COVID-19 [24]. At the end of the online ques-
tionnaire, participants were randomized to two survey experiments assessing COVID-19
vaccine hesitancy: 20% completed the same survey experiment that was fielded in June
2020 [24], and the results of this replication study are reported elsewhere [25]; 80% com-
pleted a new survey experiment, and the study results across French regions are reported
in this paper (Figure 1).
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2.2. New Survey Experiment Conducted in December 2020 
The survey experiment consisted of two sections [24]: background information on 
COVID-19 vaccination and the elicitation of vaccine acceptance based on vaccine charac-
teristics. In the first section, all participants were provided with a full page presenting 
general information about COVID-19 vaccination. In addition, participants were random-
ized to two different information blocks according to a full factorial design. In block 1, partic-
ipants were randomized to information about the collective benefits of herd immunity with a 
herd immunity target in adults aged 18–64 years (>2/3 adults, >1/2 adults, or no information) 
[26]. In block 2, participants were randomized across the general practitioner’s advice 
about COVID-19 vaccination (recommendation or no opinion) [27,28]. 
In the second section, COVID-19 vaccine acceptance was elicited using a discrete 
choice experiment [29]. Participants completed a series of eight tasks. In each task, they 
chose between having one of two hypothetical vaccines or no vaccination. As compared 
to our previous survey experiment [24], the hypothetical vaccines differed on five rather 
than four characteristics (the duration of immunity conferred by vaccination was added) 
and four rather than two levels of vaccine safety. The five characteristics (levels) were 
vaccine efficacy to reduce COVID-19 risk (50%, 80%, 90%, or 100%); vaccine safety regard-
ing the risk serious side-effects (unknown, 1/10,000, 1/100,000, or 1/1,000,000 vaccinated 
people); country of the vaccine manufacturer (headquarters in EU, United States of Amer-
ica (USA), or China); place of administration (general practitioner practice, local phar-
macy, or mass vaccination center); and duration of vaccine immunity (booster needed 
every 6 months, booster needed every year, or no booster needed). 
Based on these vaccine characteristics and levels, there were 432 hypothetical vac-
cines and 93,096 possible choice tasks between two hypothetical vaccines. A D-efficient 
experimental design was created with NGENE software (ChoiceMetrics, Sydney, NSW, 
Australia, 2014) to reduce these to 16 choice tasks with 32 hypothetical vaccines, and par-
ticipants were randomized to one of two blocks of eight task choices (Supplementary Ta-
ble S1). A choice task example is provided in Figure 2.  
Representative sample of
French adults aged 18–64 years
surveyed in December 2020
n  = 6007
Exclusion: prior SARS-CoV-2 infection
n  = 488 (8.1%)
Sample without prior
SARS-CoV-2 infection
n  = 5519
Random allocation (4:1) to
2 survey experiments
New survey experiment:
Herd immunity target: >2/3 adults aged 18–64, >1/2 adults aged 18–64, no information
General practionner's advice: recommendation of vaccination, no opinion
Discrete choice experiment with five attributes of vaccination:
- Vaccine efficacy: 50%, 80%, 90%, 100%
- Risk of serious side effects per 100,000: unknown, 10, 1, 0.1
- Location of vaccine manufacturer: EU, USA, China
- Place of vaccine administration: general practionner, pharmacy, mass vaccination 
centre
- Duration of vaccine immunity: 6 months, 1 year, 5 years
Previous survey experiment (same survey experiment as in June 2020):
Herd immunity target: >1/2 adults aged 18–64, no information
General practionner's advice: recommendation of vaccination, no opinion
Discrete choice experiment with four attributes of vaccination:
- Vaccine efficacy: 50%, 80%, 90%, 100%
- Risk of serious side effects per 100,000: 10, 1
- Location of vaccine manufacturer: EU, USA, China
- Place of vaccine administration: general practionner, pharmacy, mass vaccination 
centre
n  = 4415 (80%) n  = 1104 (20%)
Figure 1. Study flo chart.
2.2. ew Survey Experi ent Conducted in ece ber 2020
The survey experi ent consisted of t o sections [24]: background infor ation on
COVID-19 vaccination and the elicitation of vaccine acceptance based on vaccine character-
istics. In the first section, all participants were provided with a full page presenting general
information about COVID-19 vaccination. In addition, participants were randomized to
two different information blocks according to a full factorial design. In block 1, participants
were randomized to information about the collective benefits of herd immunity with a
herd immunity target in adults aged 18–64 years (>2/3 adults, >1/2 adults, or no infor-
mation) [26]. In block 2, participants were randomized across the general practitioner’s
advice about COVID-19 vaccination (recommendation or no opinion) [27,28].
In the second section, COVID-19 vaccine acceptance was elicited using a discrete
choice experiment [29]. Participants completed a series of eight tasks. In each task, they
chose between having one of two hypothetical vaccines or no vaccination. As compared to
our previous survey experiment [24], the hypothetical vaccines differed on five rather than
four characteristics (the duration of immunity conferred by vaccination was added) and
four rather than two levels of vaccine safety. The five characteristics (levels) were vaccine
efficacy to reduce COVID-19 risk (50%, 80%, 90%, or 100%); vaccine safety regarding the
risk serious side-effects (unknown, 1/10,000, 1/100,000, or 1/1,000,000 vaccinated people);
country of the vaccine manufacturer (headquarters in EU, United States of America (USA),
or China); place of administration (general practitioner practice, local pharmacy, or mass
vaccination center); and duration of vaccine immunity (booster needed every 6 months,
booster needed every year, or no booster needed).
Based on these vaccine characteristics and levels, there were 432 hypothetical vaccines
and 93,096 possible choice tasks between two hypothetical vaccines. A D-efficient experi-
mental design was created with NGENE software (ChoiceMetrics, Sydney, NSW, Australia,
2014) to reduce these to 16 choice tasks with 32 hypothetical vaccines, and participants
were randomized to one of two blocks of eight task choices (Supplementary Table S1). A
choice task example is provided in Figure 2.
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2.3. Statistical Analysis 
The proportion of participants who reported prior SARS-CoV-2 infection was esti-
mated in the whole sample, overall and by region, with use of an exact 95% confidence 
interval (95% CI) for a binomial proportion. 
COVID-19 vaccine acceptance was estimated in the sample without prior SARS-CoV-
2 infection with use of a single hurdle repeated discrete choice model [24,30]. Briefly, this 
behavioral model is a two-part model that specifies one decision process underlying out-
right vaccination refusal (i.e., serial non-vaccination in all eight choice tasks) and another 
decision process underlying vaccine acceptance (or conversely vaccine hesitancy) depend-
ing on vaccine characteristics. The probability of outright vaccination refusal and associ-
ated independent factors was analyzed using a logit regression model. The probability of 
vaccine acceptance based on vaccine characteristics and other independent factors was 
analyzed using a conditional logit regression model for repeated discrete choices in par-
ticipants who did not refuse vaccination outright. Altogether, the two-part model pro-
vides an estimation of COVID-19 vaccine acceptance, i.e., (1-poutright vaccination refusal) × pvaccine 
acceptance. 
The same set of independent factors was used to explain both decision processes and 
included the following: region of residency, six stratification variables used in the sam-
pling procedure by region (gender, age group, educational level, household size (number 
of adults and number of children), and area of residence); 15 variables related to vaccina-
tion behavior (working status including health-care worker status, unemployment or fur-
lough because of the COVID-19 health crisis, compliance with recommended vaccinations 
in the past, vaccination against 2020/21 influenza, six risk factors for a severe form of 
COVID-19 (pregnancy, smoking status, obesity, hypertension, diabetes, and other chronic 
condition), four variables related to COVID-19 experience (COVID-19 symptoms, test for 
SARS-CoV-2 infection diagnosis, knowledge of people who got COVID-19, and curfew in 
the municipality), and perceived severity of COVID-19 if infected); and the randomized 
information blocks. 
Probabilities and 95% CI of outright vaccination refusal and COVID-19 vaccine ac-
ceptance were estimated at the sample mean, overall and by region, for the first approved 
vaccines [9]. Characteristics of the first approved vaccines differed on efficacy (Pfizer&Bi-
oNTech or Moderna: 95% vs. AstraZeneca: 60%) [9,31–33], safety (Pfizer&BioNTech or 
Moderna: 1/1,000,000 vs. AstraZeneca: 1/100,000) [9,34], country of the vaccine manufac-
turer (Pfizer or Moderna: USA vs. BioNTech or AstraZeneca: EU) [9], and place of admin-
Choice task Vaccination scenario A Vaccination scenario B No vaccination
Risk of being infected
with SARS-CoV-2
The vaccine reduces your risk of 
having COVID-19 disease by 100% 
and reduces the risk of people 
around you getting infected 
The vaccine reduces your risk of 
having COVID-19 disease by 80% 
and reduces the risk of people 
around you getting infected
Your risk of having COVID-19 
disease depends on the number of 
cases in your area and the 
protective measures you take on a 
daily basis
Risk of rare but serious side 
effects from the vaccine
The risk is
1 per 100,000 vaccinated people
The risk is
1 per 10,000 vaccinated people
You take no risk




United States of America
Not applicable
Place to be vaccinated At your general practice At mass vaccination centre Not applicable
Duration of vaccine immunity Vaccine booster every 6 months Vaccine booster every year Not applicable
What would you choose?
□  I would be vaccinated
in the scenario A
□  I would be vaccinated
in the scenario B
□  I would not be vaccinated
Figure 2. Choice task example in the discrete choice experiment used in December 2020.
2.3. Statistical Analysis
The proportion of participants who reported prior SARS-CoV-2 infection was esti-
mated in the whole sample, ove all and by region, with use of an exact 95% confidence
interval (95% CI) for a binomial proportion.
COVID-19 vaccine acceptance was estimated in the sample without prior SARS-CoV-2
infection with use of a single hurdle repeated discrete choice model [24,30]. Briefly, this be-
havioral m del is a two-part model that specifies one decisio process und rlying outright
vaccinati refusal (i.e., serial non-vaccination in all eight choice t sks) nd another deci-
sion process underlying vaccine acceptance (or conversely vaccine hesitancy) depending
on vaccine characteristics. The probability of outright vaccination refusal and associated in-
dependent factors was analyzed using a logit regression model. The probability of vaccine
acceptance ba ed on vaccine characteristi s and other independe t f ctors was analyzed
using a conditional logit regression model for repeated discrete choices in participants who
did not refuse vaccination outright. Altogether, the two-part model provides an estimation
of COVID-19 vaccine acceptance, i.e., (1 − po tright vaccination refusal) × pvaccine acceptance.
The same set of indepen t factors was used to expl in both ecision processes and
included the f llowing: regio of residency, six stratificatio variables used in the sam-
pling procedure by region (gender, age group, educational level, household size (number
of adults and number of children), and area of residence); 15 variables related to vacci-
nation behavior (working st tus including health-care worker status, unemployment or
furlough because of the COVID-19 health crisis, compliance with recommended vaccina-
tions in the past, vaccination against 2020/21 influenza, six risk factors for a severe form of
COVID-19 (pregnancy, smoking status, obesity, hypertension, diabetes, and other chronic
condition), four variables related to COVID-19 experience (COVID-19 symptoms, test for
SARS-CoV-2 infection diagn sis, knowledge of people who got COVID-19, and curfew in
the municipality), and perceived severity of COVID-19 if infected); and t e randomized
information blocks.
Probabilities and 95% CI of outright vaccination refusal and COVID-19 vaccine accep-
tance were estimated at the sample mean, overall and by region, for the first approved vac-
cines [9]. Characteristics of the first approved vaccines differed on efficacy (Pfizer&BioNTech
or Moderna: 95% vs. AstraZeneca: 60%) [9,31–33], safety (Pfizer&BioNTech or Moderna:
1/1,000,000 vs. AstraZeneca: 1/100,000) [9,34], country of the vaccine manufacturer (Pfizer
or Moderna: USA vs. BioNTech or AstraZeneca: EU) [9], and place of administration in the
initial setting of the mass vaccination campaign in France (Pfizer&BioNTech or Moderna:
mass vaccination center vs. AstraZeneca: general practitioner practice or local pharmacy).
Other vaccination characteristics were controlled for at the same level (low duration of
vaccine immunity with a booster needed every 6 months; vaccination recommended by
the general practitioner; and no information provided about the collective benefits of herd
immunity in the initial setting of the mass vaccination campaign in France).
Vaccines 2021, 9, 1364 5 of 13
All analyses were based on two-sided p-values, with p < 0.05 considered to indicate
statistical significance. The single hurdle repeated discrete choice model was estimated
using maximum likelihood techniques with R statistical software [24].
3. Results
3.1. Prevalence of Detected SARS-CoV-2 Infection in the French Working-Age Population
A representative sample of 6007 adults aged 18–64 years residing in twelve regions of
France participated in the online survey from 30 November to 16 December 2020. Of them,
8.1% (95% CI, 7.5–8.8) reported a prior SARS-CoV-2 infection (1.1% hospital admission
for COVID-19; 1.7% medical diagnosis of COVID-19 without a virology test; and 5.3%
positive test for SARS-CoV-2 infection diagnosis with (2.9%) or without (2.4%) symptoms).
The prevalence rate of detected SARS-CoV-2 infection significantly varied across regions
(p < 0.0001) according to an East–West gradient (Figure 3; Supplementary Table S2).
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Figure 3. Prevalence of detected SARS-CoV-2 infection in the French working-age population
(December 2020). Figure leg nd: Auv rgne-Rhône-Alpes (ARA), ourgogne-Franche-Comté (BFC),
Bretagne (BRE), Cen-tre-Val de Loire (CVL), Grand Est (GES), Hauts-de-France (HDF), Ile-de-France
(IDF), Normandie (NOR), Nouvelle-Aquitaine (NAQ), Occitanie (OCC), Pays-de-la-Loire (PDL), and
Provences-Alpes-Côte-d’Azur (PAC).
3.2. COVID-19 Vaccine Hesitancy in Participants without Prior SARS-CoV-2 Infection
A total of 4806 (80%) participants were randomly allocated to the new survey exper-
iment assessing COVID-19 vaccine hesitancy depending on five vaccine characteristics
(Figure 1). Of them, 4415 (91.9%) did not report prior SARS-CoV-2 infection and were
selected for the analysis of COVID-19 vaccine hesitancy. As expected from differences
between regional populations, sociodemographic characteristics of the selected partici-
pants significantly varied across regions (age: p < 0.05; education: p < 0.001; and area of
residence: p < 0.001) (Supplementary Table S3). In addition, participants residing in regions
with higher prevalence rates of detected SARS-CoV-2 infection more frequently reported
COVID-19 experience (having had COVID-19 symptoms without medical confirmation:
p < 0.001; and knowing someone who got COVID-19: p < 0.001).
A total of 1823 (41.3% (95% CI, 39.8–42.8)) participants were identified as refusing
COVID-19 vaccination outright. Outright vaccination refusal was not associated with
the region of residency in univariate (overall test: p = 0.18; Supplementary Table S4) and
multivariate analyses (overall test: p = 0.60; Table 1). By contrast, it was independently
associated with female gender (p < 0.0001), age with an inverted U-shaped relationship
(p < 0.0001), lower educational achievement (p < 0.01), poorer compliance with recom-
mended vaccinations in the past (p < 0.0001), no vaccination against 2020/21 influenza
(p < 0.0001), and lower perceived severity of COVID-19 if infected (p < 0.0001).
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Table 1. Behavioral model of COVID-19 vaccination in the French working-age population without prior SARS-CoV-2 infection in December 2020 (n = 4415).
Outright Refusal of COVID-19 Vaccination (41.3%) COVID-19 Vaccine Hesitancy (58.7%)
Determinants of COVID-19 Vaccination OR (95% CI) p-Value OR (95% CI) p-Value
French region of residency (ordered by detected SARS-CoV-2 prevalence)
Normandie (NOR) (ref. Ile-de-France) 0.92 (0.65–1.31) 0.66 0.92 (0.8–1.10) 0.36
Bretagne (BRE) (ref. Ile-de-France) 0.79 (0.53–1.16) 0.23 0.84 (0.73–1.00) 0.079
Centre-Val de Loire (CVL) (ref. Ile-de-France) 0.81 (0.53–1.23) 0.32 1.09 (0.89–1.39) 0.42
Pays-de-la-Loire (PDL) (ref. Ile-de-France) 0.73 (0.49–1.06) 0.10 1.12 (0.93–1.41) 0.21
Nouvelle-Aquitaine (NAQ) (ref. Ile-de-France) 1.05 (0.74–1.49) 0.79 1.02 (0.86–1.23) 0.85
Bourgogne-Franche-Comté (BFC) (ref. Ile-de-France) 0.92 (0.61–1.38) 0.69 1.22 (1.00–1.61) 0.041
Grand Est (GES) (ref. Ile-de-France) 0.88 (0.63–1.23) 0.47 0.97 (0.84–1.16) 0.75
Occitanie (OCC) (ref. Ile-de-France) 1.10 (0.83–1.47) 0.50 1.23 (1.05–1.49) 0.004
Provence-Alpes-Côte-d’Azur (PAC) (ref. Ile-de-France) 0.96 (0.70–1.32) 0.82 1.02 (0.89–1.21) 0.76
Hauts-de-France (HDF) (ref. Ile-de-France) 0.97 (0.73–1.30) 0.85 0.99 (0.87–1.15) 0.91
Auvergne-Rhône-Alpes (ARA) (ref. Ile-de-France) 1.05 (0.81–1.36) 0.72 1.01 (0.90–1.16) 0.88
Vaccine characteristics
Vaccine efficacy of 80% (ref. 50%)
Not applicable
0.58 (0.56–0.60) <0.0001
Vaccine efficacy of 90% (ref. 50%) 0.44 (0.43–0.45) <0.0001
Vaccine efficacy of 100% (ref. 50%) 0.33 (0.32–0.34) <0.0001
Vaccine booster every year (ref. booster every 6 months) 0.95 (0.90–0.99) 0.029
No vaccine booster needed (ref. booster every 6 months) 0.78 (0.75–0.81) <0.0001
Unknown risk of serious side effects (ref. 1/10,000) 1.54 (1.40–1.71) <0.0001
Risk of serious side effects of 1/100,000 (ref. 1/10,000) 0.76 (0.73–0.80) <0.0001
Risk of serious side effects of 1/1,000,000 (ref. 1/10,000) 0.57 (0.55–0.59) <0.0001
Vaccine made in USA (ref. European Union) 1.59 (1.44–1.77) <0.0001
Vaccine made in China (ref. European Union) 2.40 (2.13–2.74) <0.0001
Vaccination at GP practice (ref. mass vaccination center) 0.98 (0.93–1.03) 0.42
Vaccination at local pharmacy (ref. mass vaccination center) 0.98 (0.93–1.03) 0.37
Background information on COVID-19 vaccination
>67% of adults aged 18–64 years old must be immunized to reach herd immunity (ref. no information) 0.89 (0.76–1.04) 0.16 0.92 (0.86–0.99) 0.029
>50% of adults aged 18–64 years old must be immunized to reach herd immunity (ref. no information) 0.99 (0.84–1.16) 0.88 1.05 (0.97–1.14) 0.22
General practitioner recommends vaccination (ref. no opinion) 1.01 (0.88–1.15) 0.90 1.02 (0.96–1.09) 0.52
Survey stratification variables (by region of residency)
Men (ref. women) 0.55 (0.48–0.64) <0.0001 0.71 (0.67–0.74) <0.0001
25–34 years (ref. 18–24) 1.60 (1.21–2.12) 0.001 1.02 (0.90–1.18) 0.81
35–44 years (ref. 18–24) 1.70 (1.28–2.26) 0.0003 1.04 (0.91–1.20) 0.61
45–54 years (ref. 18–24) 1.69 (1.28–2.24) 0.0002 0.89 (0.79–1.00) 0.08
55–64 years (ref. 18–24) 1.48 (1.11–1.99) 0.008 0.86 (0.77–0.98) 0.04
High school graduate (ref. some high school) 0.89 (0.75–1.06) 0.20 0.86 (0.80–0.93) 0.001
University graduate (ref. some high school) 0.75 (0.62–0.90) 0.002 0.88 (0.82–0.96) 0.007
Number of adults in the household 0.98 (0.88–1.09) 0.74 1.11 (1.05–1.18) <0.0001
Number of children in the household 1.02 (0.94–1.11) 0.57 1.01 (0.98–1.06) 0.48
Urban area <100,000 inhabitants (ref. rural area) 0.94 (0.78–1.13) 0.53 1.00 (0.92–1.10) 0.97
Urban area ≥100,000 inhabitants (ref. rural area) 0.78 (0.64–0.94) 0.010 0.98 (0.90–1.08) 0.66
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Table 1. Cont.
Outright Refusal of COVID-19 Vaccination (41.3%) COVID-19 Vaccine Hesitancy (58.7%)
Determinants of COVID-19 Vaccination OR (95% CI) p-Value OR (95% CI) p-Value
Variables related to vaccination behavior
Healthcare worker (ref. not working) 1.01 (0.78–1.31) 0.93 1.25 (1.08–1.49) 0.0005
Worker in contact with the public (ref. not working) 0.95 (0.78–1.14) 0.56 1.14 (1.03–1.27) 0.005
Worker not in contact with the public (ref. not working) 1.08 (0.89–1.3) 0.45 1.14 (1.03–1.27) 0.009
Unemployed or furloughed because of the COVID-19 health crisis (ref. not reported) 0.97 (0.81–1.16) 0.76 0.95 (0.87–1.03) 0.20
Sometimes compliant with recommended vaccination in the past (ref. always) 2.15 (1.86–2.48) <0.0001 1.61 (1.45–1.82) <0.0001
Never compliant with recommended vaccination in the past (ref. always) 5.21 (4.22–6.44) <0.0001 2.92 (2.16–4.51) <0.0001
Vaccination against influenza 2020/2021 (ref. not reported) 0.54 (0.42–0.67) <0.0001 0.61 (0.58–0.65) <0.0001
Pregnancy (ref. not reported) 1.46 (0.73–2.97) 0.28 1.37 (0.91–2.82) 0.10
Current smoker (ref. never smoker) 0.93 (0.79–1.10) 0.40 1.04 (0.95–1.13) 0.41
Former smoker (ref. never smoker) 0.96 (0.82–1.12) 0.62 1.13 (1.04–1.24) 0.002
Obese (ref. normal weight) 1.04 (0.86–1.26) 0.68 1.05 (0.96–1.16) 0.29
Overweight (ref. normal weight) 1.15 (0.99–1.34) 0.07 1.14 (1.05–1.24) 0.0006
Hypertension (ref. not reported) 0.77 (0.59–1.00) 0.050 0.84 (0.76–0.93) 0.004
Diabetes (ref. not reported) 0.80 (0.55–1.15) 0.23 1.09 (0.93–1.32) 0.31
Other chronic condition (ref. not reported) 0.99 (0.76–1.28) 0.92 1.09 (0.96–1.25) 0.17
Had COVID-19 symptoms (ref. not reported) 0.95 (0.79–1.13) 0.54 1.10 (1.00–1.21) 0.031
Had a test for SARS-CoV-2 infection diagnosis (ref. not reported) 1.01 (0.84–1.20) 0.94 0.83 (0.78–0.90) <0.0001
Knows someone who got COVID-19 with hospital admission (ref. not reported) 0.81 (0.67–0.98) 0.032 1.12 (1.01–1.25) 0.018
Knows someone who got COVID-19 without hospital admission (ref. not reported) 0.9 (0.77–1.04) 0.15 1.07 (1.00–1.17) 0.06
Curfew in the municipality after 17 October 2020 (ref. after 15 December 2020) 0.94 (0.73–1.23) 0.67 0.92 (0.82–1.04) 0.21
Curfew in the municipality after 28 October 2020 (ref. after 15 December 2020) 0.94 (0.78–1.14) 0.53 0.87 (0.81–0.95) 0.005
Perceived severity of COVID-19 if infected
Very severe (ref. Not severe at all) 0.46 (0.32–0.65) <0.0001 0.72 (0.64–0.82) 0.0001
Somewhat severe (ref. Not severe at all) 0.55 (0.43–0.71) <0.0001 0.65 (0.60–0.71) <0.0001
Not particularly severe (ref. Not severe at all) 0.74 (0.58–0.94) 0.015 0.75 (0.69–0.83) <0.0001
Don’t know (ref. Not severe at all) 0.82 (0.63–1.08) 0.16 1.09 (0.94–1.28) 0.24
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Among 2592 (58.7%) participants who did not refuse vaccination outright, vaccine
hesitancy was associated with the region of residency (overall test: p < 0.01; Table 1) due
to two outlier regions with higher vaccine hesitancy: Bourgogne-Franche-Comté (BFC)
(p < 0.05) and Occitanie (OCC) (p < 0.01). By contrast, vaccine hesitancy was primarily
decreased with higher vaccine efficacy, lower risk of serious side-effects, vaccines made in
EU rather than USA (or China), and, to a lesser extent, longer duration of vaccine immunity
(all p < 0.0001). In addition, sociodemographic and attitudinal factors associated with
outright vaccination refusal were also strongly associated with vaccine hesitancy, albeit
strengths of association were generally weaker with vaccine hesitancy.
3.3. COVID-19 Vaccine Acceptance Predicted in December 2020
In the initial setting of the mass vaccination campaign in France, the behavioral model
predicted that outright refusal of COVID-19 vaccination would be present in 42.1% (95%
CI, 41.6–42.7) of the French working-age population without prior SARS-CoV-2 infection
(Figure 4). According to the characteristics of the first approved vaccines, COVID-19 vaccine
acceptance would reach at best 43.6% (95% CI, 43.0–44.1) for a BioNTech vaccine promoted
as made in EU rather than USA (Figure 4) and would be lower for Pfizer or Moderna
vaccines (38.4% (95% CI, 37.8–38.9)); Supplementary Figure S1) and the AstraZeneca
vaccine (31.1% (95% CI, 30.6–31.6)); Supplementary Figure S2).
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Figure 4. Acceptance of BioNTech vaccine predicted in the French working-age population, overall and by region (December
2020). Figure legend: Auvergne-Rhône-Alpes (ARA), Bourgogne-Franche-Comté (BFC), Bretagne (BRE), Cen-tre-Val de
Loire (CVL), Grand Est (GES), Hauts-de-France (HDF), Ile-de-France (IDF), Normandie (NOR), Nouvelle-Aquitaine (NAQ),
Occitani (OCC), Pays-de-la-Loire (PDL), and Provences-Alpes-Côte-d’Azur (PAC). French regions of residency are ordered
by detected SARS-CoV-2 prevalence.
Acceptance of a BioNTech vaccine was estimated at the sample mean of each region of
residency. Figure 4 presents regional estimates ordered by increasing prevalence of detected
SARS-CoV-2 infection. Outright refusal of COVID-19 vaccination would significantly
decrease from 48.0% (95% CI, 46.1–49.9) in Occitanie (OCC) to 37.9% (95% CI, 35.7–40.1)
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in Pays-de-la-Loire (PDL), although it was not correlated with the prevalence of detected
SARS-CoV-2 infection (ρ = 0.27; p = 0.40). Similarly, acceptance of a BioNTech vaccine
would significantly increase from 37.2% (95% CI, 35.4–39.0) in Occitanie (OCC) to 48.9%
(95% CI, 46.5–51.3) in Bretagne (BRE), although it was not correlated with the prevalence of
detected SARS-CoV-2 infection (ρ = −0.26; p = 0.42).
4. Discussion
In this large and representative survey of 6007 adults aged 18–64 years and residing
in France, 8.1% (95% CI, 7.5–8.8) reported a prior SARS-CoV-2 infection in December 2020,
with regional variations according to an East–West gradient (p < 0.0001). In participants
without prior SARS-CoV-2 infection, COVID-19 vaccine hesitancy was substantial, includ-
ing 41.3% (95% CI, 39.8–42.8) outright refusal of COVID-19 vaccination. Taking into account
five characteristics of the first approved vaccines (efficacy, duration of immunity, safety,
country of the vaccine manufacturer, and place of administration) as well as the initial
setting of the mass vaccination campaign in France, COVID-19 vaccine acceptance would
reach 43.6% (95% CI, 43.0–44.1) at best among working-age adults without prior SARS-CoV-
2 infection. COVID-19 vaccine acceptance was primarily driven by vaccine characteristics,
sociodemographic and attitudinal factors. Considering the region of residency as a proxy
of the likelihood of getting infected, our study findings do not support the assumption that
SARS-CoV-2 infection risk is associated with COVID-19 vaccine acceptance.
To our knowledge, this is the first study assessing the association between SARS-CoV-2
infection risk and COVID-19 vaccination intentions. France provides a natural experiment
to assess this association as SARS-CoV-2 pandemic initially spread in the North–East and
Ile-de-France regions and was controlled by a nationwide lockdown ordered on 17 March
2020 [2]. Accordingly, the heterogeneity of SARS-CoV-2 infection rates across regions was
high after the first wave (11 May 2020) and only marginally reduced during the second
wave (31 October 2020) [22]. In our study, 8.1% (95% CI, 7.5–8.8) of participants reported
a prior SARS-CoV-2 infection during the second wave of the SARS-CoV-2 pandemic in
December 2020. In comparison, the detection rate of SARS-CoV-2 infection in the French
working-age population was similarly estimated at 7.8% (95% CI, 6.0–10.0) as of 15 January
2021 in an epidemiological modeling study [22]. In addition, the external validity of our
study was enhanced by the significant correlation of regional estimates between the two
studies (ρ = 0.81; p < 0.01) (Supplementary Table S2).
We assessed COVID-19 vaccination intentions in participants without prior SARS-CoV-
2 infection with use of a two-part behavioral model [24]. As compared to opinion surveys
asking about vaccination intentions for vaccines with unspecified characteristics [16–18],
it allowed the identification of participants who would never choose to be vaccinated
regardless of five vaccine characteristics (outright refusal of vaccination) and those who are
hesitant and whose choice to be vaccinated would depend on vaccine characteristics [9]. In
participants who did not refuse vaccination outright, we found that vaccine efficacy, vaccine
safety, and the country of the vaccine manufacturer were primary drivers of COVID-19
vaccine acceptance as in previous discrete choice experiments [24,25,35–38]. In addition,
participants were randomly allocated to two discrete choice experiment designs presenting
five (80%) vs. four (20%) vaccine characteristics (Figure 1), and we found robust estimates
across the two survey experiments regarding outright refusal of vaccination (41.3% (95%
CI, 39.8–42.8)) vs. 42.5% (95% CI, 41.1–43.8), respectively) and overall acceptance of
the best (BioNTech) vaccine (43.6% (95% CI, 43.0–44.1) vs. 44.0% (95% CI, 42.7–45.2),
respectively) [25].
Our study findings do not support the assumption that SARS-CoV-2 infection risk is
associated with COVID-19 vaccination intentions in the working-age population. At the
individual level, the region of residency was not an independent predictor of outright vacci-
nation refusal. Two regions (Bourgogne-Franche-Comté and Occitanie) were independently
associated with higher vaccine hesitancy as compared to other regions. However, they
were in the middle range rather than the ends of prevalence rates of detected SARS-CoV-2
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infection (Supplementary Table S2). At the macro level, COVID-19 vaccine acceptance
significantly varied across regions, although it was uncorrelated with prevalence rates
of detected SARS-CoV-2 infection (ρ = −0.26; p = 0.42). By contrast, regional variations
in COVID-19 vaccine acceptance were primarily explained by differences on sociodemo-
graphic characteristics (age, education, and area of residency) that were in turn consistently
associated with COVID-19 vaccine hesitancy [24,25].
The main limitation of our study relates to its timing. COVID-19 vaccination intentions
may continuously evolve in relation to the dynamic of the SARS-CoV-2 pandemic and
associated non-pharmaceutical interventions [2,3] as well as information on COVID-19 vac-
cine uptake made available to the public in almost real-time [39]. Nevertheless, our study
findings support that COVID-19 vaccine hesitancy was profoundly anchored in multiple,
large sociodemographic strata of the working-age population (women, 25–54 years old,
lower educational achievement, rural areas) before mass vaccination started in the elderly
in France.
Another limitation is that sample size was limited in regions that are sparsely popu-
lated, with a minimum of 234 (3.9%) participants in the Centre-Val de Loire (CVL) region.
However, the study was conducted among the working-age population who is at high risk
of SARS-CoV-2 infection as compared to the elderly [22,23]. To avoid spurious associa-
tion, we excluded participants reporting prior SARS-CoV-2 infection from the analysis of
COVID-19 vaccine hesitancy as they were excluded from vaccine phase 3 trials [31–33], and
vaccination was not recommended for them in the initial setting of the mass vaccination
campaign in France [40]. In addition, our behavioral model of COVID-19 vaccine hesi-
tancy was controlled for a large set of independent factors including COVID-19 experience
and the perceived severity of COVID-19 that may confound the association between the
likelihood of getting infected and COVID-19 vaccination intentions [19–21].
Finally, Corsica was not included in our study as this region was underrepresented
in the BVA online survey research panel. Corsica accounts for 0.5% of the working-age
population in France (2020 national census data), and its inclusion may have biased our
correlation estimate between the prevalence of detected SARS-CoV-2 infection and COVID-
19 vaccination hesitancy at the regional level. In addition, Corsica was associated with one
of the lowest detection rates of SARS-CoV-2 infection as of 15 January 2021 (4.0% (95% CI,
3.1–5.3) of the working-age population) [22] but remained in the middle range of COVID-19
vaccination coverage recorded by region (e.g., 42.2% as compared to 43.4% (min: 40.0%;
max: 47.0%) of the working-age population in other regions of metropolitan France as of
11 July 2021) [41], further supporting that there is no association between SARS-CoV-2
infection risk and COVID-19 vaccination in the working-age population.
In summary, our survey experiment supports that COVID-19 vaccine hesitancy was
deeply anchored in the French working-age population in December 2020 and primarily
driven by vaccine characteristics, sociodemographic and attitudinal factors, but unrelated
to SARS-CoV-2 infection risk at the rather low levels estimated in 2020. Accordingly, French
regions that were initially spared during the first wave of SARS-CoV-2 pandemic may
remain at high risk of local outbreaks of SARS-CoV-2 pandemic despite availability of
COVID-19 vaccination services [10–12].
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/vaccines9111364/s1, Table S1: Prevalence of detected SARS-CoV-2 infection in the French
working age population, Table S2: Characteristics of participants without prior SARS-CoV-2 infection
by region of residency (December 2020, France), Table S3: Outright refusal of COVID-19 vaccination
(December 2020, France), Table S4. Outright refusal of COVID-19 vaccination (December 2020,
France), Figure S1: Acceptance of Pfizer or Moderna vaccines predicted in the working age population
(December 2020, France), Figure S2: Acceptance of AstraZeneca vaccine predicted in the working age
population (December 2020, France).
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